Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections

Jon P. Furuno,a Gregory B. Tallman,a Brie N. Noble,a Joseph S. Bubalo,b Graeme N. Forrest,c James S. Lewis II,b Ana F. Bienvenida,a,b Courtney A. Holmes,a Bo R. Weber,a,b Jessina C. McGregor,a

aDepartment of Pharmacy Practice, Oregon State University/Oregon Health & Science University College of Pharmacy, Portland, Oregon, USA
bDepartment of Pharmacy Services, Oregon Health & Science University Hospitals and Clinics, Portland, Oregon, USA
cDivision of Infectious Diseases, VA Portland Healthcare System, Portland, Oregon, USA

ABSTRACT Posaconazole is used for prophylaxis for invasive fungal infections (IFIs) among patients with hematologic malignancies. We compared the incidence of breakthrough IFIs and early discontinuation between patients receiving delayed-release tablet and oral suspension formulations of posaconazole. This was a retrospective cohort study of patients receiving posaconazole between 1 January 2010 and 30 June 2016. We defined probable or proven breakthrough IFIs using the EORTC criteria. Overall, 547 patients received 860 courses of posaconazole (53% received the oral suspension and 48% received the tablet); primary indications for prophylaxis were acute myeloid leukemia (69%), graft-versus-host disease (18%), and myelodysplastic syndrome (3%). There were no significant differences in demographics or indications between patients receiving the different formulations. The incidence and incidence rate of probable or proven IFIs were 1.6% and 3.2 per 10,000 posaconazole days, respectively. There was no significant difference in the rate of IFIs between suspension courses (2.8 per 10,000 posaconazole days) and tablet courses (3.7 per 10,000 posaconazole days) (rate ratio = 0.8, 95% confidence interval [CI] = 0.3 to 2.3). Of the 14 proven or probable cases of IFI, 8/14 had posaconazole serum concentrations measured, and the concentrations in 7/8 were above 0.7 μg/ml. Posaconazole was discontinued early in 15.5% of courses; however, the frequency of discontinuation was also not significantly different between the tablet (16.5%) and oral suspension (14.6%) formulations (95% CI for difference = −0.13 to 0.06). In conclusion, the incidence of breakthrough IFIs was low among patients receiving posaconazole prophylaxis and not significantly different between patients receiving the tablet formulation and those receiving the oral suspension formulation.

KEYWORDS antifungal agents, formulation, invasive fungal infection, medical outcomes, posaconazole, prophylaxis

Invasive fungal infections (IFIs) are associated with considerable excess morbidity, mortality, and costs among infected patients. Immunocompromised patients, including patients with hematologic malignancies receiving hematopoietic stem cell transplants and immunosuppressive therapy, are at increased risk of IFIs and associated poor outcomes (1–3). Posaconazole prophylaxis has been recommended to prevent IFIs and improve patient outcomes in these high-risk patients (4, 5). A randomized controlled trial concluded that posaconazole more effectively prevented IFIs and was associated...
with lower all-cause mortality than fluconazole or itraconazole among neutropenic patients (6).

The suboptimal absorption of the oral suspension formulation of posaconazole and the requirements of the dosing regimen may have limited its effectiveness. A delayed-release tablet formulation of posaconazole was approved in December 2013, and previous studies have suggested that this formulation improves absorption and bioavailability (7, 8). However, improved clinical outcomes with the tablet formulation compared to the oral suspension have not been clearly demonstrated. In this study, we expand upon prior work performed at Oregon Health & Science University Hospitals and Clinics (OHSU) to assess the clinical outcomes between the oral suspension and tablet formulations of posaconazole for prophylaxis for IFIs. We also identified and compared the frequency and rationale for discontinuation of posaconazole and postdiscontinuation outcomes between patients receiving the different formulations of posaconazole prophylaxis.

(These data were presented in part at ASM Microbe 2017, June 2017, New Orleans, LA, and IDWeek 2017, October 2017, San Diego, CA.)

RESULTS

We initially identified 664 patients, which represented 2,097 potential courses of posaconazole, for possible inclusion in this study. However, following application of our exclusion criteria (Fig. 1), our final sample size was 547 patients representing 860 courses of posaconazole, of which 452 courses (52.6%) were the oral suspension formulation and 408 courses (48.4%) were the tablet formulation. Included patients were more frequently male (61.8%) and had a median Charlson comorbidity index of 3 (interquartile range [IQR], 2 to 5) (data not shown). The course-level characteristics of the patients stratified by posaconazole formulation are displayed in Table 1. Patients who received the tablet formulation were more likely to be greater than 65 years old than patients who received suspension courses (27.7% versus 21.9%, \( P = 0.049 \)). Additionally, patients who received oral suspension courses were more likely to receive nasogastric tube administration of posaconazole than patients who received the tablet
In contrast, patients receiving posaconazole suspension courses were less likely than patients receiving tablet courses to have nasogastric tube administration (2.9% versus 0.7%, \( P \leq 0.02 \)) and a diagnosis of mucositis during their course (15.7% versus 8.9%, \( P \leq 0.002 \)). In contrast, patients receiving posaconazole suspension courses were less likely than patients receiving tablet courses to have nasogastric tube administration (2.9% versus 0.7%, \( P \leq 0.02 \)) and a diagnosis of mucositis during their course (15.7% versus 8.9%, \( P \leq 0.002 \)).

### TABLE 1 Characteristics of posaconazole courses

| Characteristic                                                                 | Value for patients receiving:                                                                 |
|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| No. (％) of courses among patients aged >65 yr                                | **Total** (\( n = 860 \))  \| **Oral suspension** (\( n = 452 \))  \| **Tablet** (\( n = 408 \))  \| **P** |
| No. (％) of courses among patients with BMI of >30 kg/m²                       | 212 (24.7)  \| 99 (21.9)  \| 113 (27.7)  \| 0.049 |
| Median (IQR) Charlson comorbidity index                                       | 280 (32.6)  \| 153 (33.9)  \| 127 (31.1)  \| 0.40 |
| Median (IQR) duration of prophylaxis (days)                                  | 3 (2–5)  \| 3 (2–5)  \| 3 (2–5)  \| 0.34 |
| Median (IQR) duration of prophylaxis (days)                                  | 25 (15–52)  \| 24 (14–54.5)  \| 25 (15–49)  \| 0.93 |
| No. (％) of courses among patients with nasogastric tube administration       | 16 (1.9)  \| 13 (2.9)  \| 3 (0.7)  \| 0.02 |
| No. (％) of courses among patients with the following prophylaxis indication: |                                                                                             |
| Acute myeloid leukemia                                                        | 590 (68.6)  \| 305 (67.5)  \| 285 (69.9)  \| 0.19 |
| Graft-vs-host disease                                                         | 153 (18.0)  \| 84 (18.6)  \| 71 (17.4)  \| 0.86 |
| Myelodysplastic syndrome                                                      | 27 (3.1)  \| 14 (3.1)  \| 13 (3.2)  \| 0.32 |
| Acute lymphoblastic leukemia                                                  | 25 (2.9)  \| 15 (3.3)  \| 10 (2.5)  \| 0.25 |
| Aplastic anemia                                                              | 17 (2.0)  \| 10 (2.2)  \| 7 (1.7)  \| 0.17 |
| Other high-dose steroid use                                                   | 12 (1.4)  \| 3 (0.7)  \| 9 (2.2)  \| 0.05 |
| Other leukemia                                                                | 12 (1.4)  \| 10 (2.2)  \| 2 (0.5)  \| 0.02 |
| Post-allogeneic hematopoietic stem cell transplant                            | 12 (1.4)  \| 4 (0.9)  \| 8 (2.0)  \| 0.04 |
| Chronic myeloid leukemia                                                     | 4 (0.5)  \| 4 (0.9)  \| 0 (0.0)  \| 0.06 |
| Chronic lymphocytic leukemia                                                  | 2 (0.2)  \| 1 (0.2)  \| 1 (0.3)  \| 0.30 |
| Multiple myeloma                                                             | 2 (0.2)  \| 1 (0.2)  \| 1 (0.3)  \| 0.30 |
| Other                                                                        | 2 (0.2)  \| 1 (0.2)  \| 1 (0.3)  \| 0.30 |
| Met NCCN criteria for prophylaxis                                             | 754 (87.7)  \| 390 (86.3)  \| 364 (89.2)  \| 0.14 |
| Mucositis during course                                                      | 106 (12.3)  \| 71 (15.7)  \| 35 (8.9)  \| 0.002 |
| No. (％) of courses among patients receiving the following other medications: |                                                                                             |
| Antiviral therapy                                                            | 641 (74.5)  \| 338 (74.8)  \| 303 (74.3)  \| 0.86 |
| Antibiotic therapy                                                           | 764 (88.8)  \| 413 (91.4)  \| 351 (86.0)  \| 0.01 |
| Proton pump inhibitors                                                       | 457 (53.1)  \| 250 (55.3)  \| 207 (50.7)  \| 0.18 |
| No. (％) of courses among patients:                                           |                                                                                             |
| In whom the posaconazole serum concn was measured during the course          | 486 (56.5)  \| 210 (46.5)  \| 276 (67.6)  \| <0.001 |
| Who achieved the target serum concn (≥0.7 mg/liter) (\( n = 486 \))          | 377 (77.6)  \| 127 (60.5)  \| 250 (90.6)  \| <0.001 |
| No. (％) of courses among patients with the following chemotherapy regimen (\( n = 566 \)): | 0.48 |
| Cytarabine + idarubicin ± methotrexate                                        | 198 (35.0)  \| 103 (35.4)  \| 95 (34.5)  \| 0.48 |
| Cytarabine ± methotrexate                                                     | 144 (25.4)  \| 78 (26.8)  \| 66 (24.0)  \| 0.48 |
| Cytarabine + idarubicin + fludarabine ± methotrexate                         | 46 (8.1)  \| 22 (7.6)  \| 24 (8.7)  \| 0.48 |
| Cytarabine + mitoxantrone + etoposide ± methotrexate                         | 34 (6.0)  \| 15 (5.2)  \| 19 (6.9)  \| 0.48 |
| Other                                                                        | 23 (4.1)  \| 14 (4.8)  \| 9 (3.3)  \| 0.48 |
| Azacitidine                                                                  | 22 (3.9)  \| 11 (3.8)  \| 11 (4.0)  \| 0.48 |
| Cytarabine + mitoxantrone ± methotrexate                                     | 19 (3.4)  \| 8 (2.7)  \| 11 (4.0)  \| 0.48 |
| Cytarabine + fludarabine                                                     | 13 (2.3)  \| 7 (2.4)  \| 6 (2.2)  \| 0.48 |
| Cytarabine + daunorubicin                                                    | 12 (2.1)  \| 4 (1.4)  \| 8 (2.9)  \| 0.48 |
| Cytarabine + idarubicin + mitoxantrone + etoposide                          | 11 (1.9)  \| 6 (2.1)  \| 5 (1.8)  \| 0.48 |
| Azacitidine + cytarabine + idarubicin ± methotrexate                         | 10 (1.8)  \| 5 (1.7)  \| 5 (1.8)  \| 0.48 |
| Methotrexate                                                                | 10 (1.8)  \| 6 (2.1)  \| 4 (1.5)  \| 0.48 |
| Cytarabine + idarubicin + tretinoin ± methotrexate                           | 8 (1.4)  \| 3 (1.0)  \| 5 (1.8)  \| 0.48 |
| Fludarabine                                                                 | 5 (0.9)  \| 2 (0.7)  \| 3 (1.1)  \| 0.48 |
| Idarubicin + tretinoin                                                       | 5 (0.9)  \| 5 (1.7)  \| 0 (0.0)  \| 0.48 |
| Cytarabine + etoposide                                                       | 2 (0.4)  \| 0 (0.0)  \| 2 (0.7)  \| 0.48 |
| Fludarabine + cytarabine + mitoxantrone + etoposide                         | 2 (0.4)  \| 0 (0.0)  \| 2 (0.7)  \| 0.48 |
| Fludarabine + cytarabine + mitoxantrone + etoposide + methotrexate + idarubic | 2 (0.4)  \| 2 (0.7)  \| 0 (0.0)  \| 0.48 |

\(<\text{Data are for } 860 \text{ courses. BMI, body mass index; IQR, interquartile range; NCCN, National Comprehensive Cancer Network.}\)
patients receiving tablet courses to have posaconazole serum concentrations measured (46.5% versus 67.6%, \( P < 0.001 \)). Among those with serum concentration measurements, patients receiving suspension posaconazole courses were less likely to have achieved a target level of \( \geq 0.7 \) mg/liter (60.5% versus 90.6%, \( P < 0.001 \)). There was no significant difference in the Charlson comorbidity index between formulations in both groups (median, 3; IQR, 2 to 5; \( P = 0.34 \)).

We identified 57 patients to be candidates for having an IFI that were subsequently reviewed by the expert panel. Following review by our clinical expert panel, 14 were determined to have a probable or proven IFI. Specifically, there were 3 probable and 4 proven cases of IFIs among patients receiving the suspension and 1 probable and 6 proven cases among patients receiving the tablet formulation. The incidence and incidence rate of probable or proven IFIs were 1.6% and 3.2 cases per 10,000 posaconazole days (95% confidence interval \([1.8 \text{ to } 5.4 \text{ cases per 10,000 posaconazole days}]\), respectively. There was no significant difference in the rate of IFIs between suspension courses (2.8 per 10,000 posaconazole days) and tablet courses (3.7 per 10,000 posaconazole days) (rate ratio \( \text{RR} = 0.8, 95\% \text{ CI} = 0.3 \text{ to } 2.3 \)). Results from unadjusted and adjusted Cox proportional hazards regression models of the effect of formulation on the risk of breakthrough IFIs are shown in Table 2. Tablet courses were more likely to be associated with breakthrough IFIs than suspension courses (adjusted hazard ratio \( \text{HR} = 1.2, 95\% \text{ CI} = 0.4 \text{ to } 3.4 \)), although this difference was not statistically significant. Nasogastric tube administration was significantly associated with an increased likelihood of breakthrough IFIs (adjusted \( \text{HR} = 34.1, 95\% \text{ CI} = 6.3 \text{ to } 128.9 \)) ; however, only 16 (1.9%) courses had nasogastric tube administration. Additionally, an age of \( \geq 65 \) years (adjusted \( \text{HR} = 3.7, 95\% \text{ CI} = 1.2 \text{ to } 12.1 \)) and mucositis (adjusted \( \text{HR} = 4.6, 95\% \text{ CI} = 1.0 \text{ to } 17.5 \)) were associated with a statistically significantly increased likelihood of breakthrough IFIs. Results from the sensitivity analysis including only the first course of posaconazole prophylaxis per patient \((n = 547)\) were not meaningfully different from results including all posaconazole courses; i.e., the estimates from both models were similar in direction and magnitude (data not shown).

A description of the 14 cases of breakthrough IFIs is shown in Table 3. The majority of cases were classified as proven IFIs (71.4%), and the most prevalent site of infection was the lung (50%). The median length of prophylaxis prior to breakthrough IFIs was 16 days (IQR, 13 to 40 days). Only 8/14 (57%) cases had posaconazole serum concentrations measured during their course, of which 7 (87.5%) reached the target concentration of \( \geq 0.7 \) mg/liter. Antifungal susceptibility data were available for 4 of the 10 cases of proven IFIs. MICs of 0.5 \( \mu \text{g/ml} \) (Candida tropicalis) and 1 \( \mu \text{g/ml} \) (Candida glabrata) were observed for the two tested yeast isolates, and MICs of 1 \( \mu \text{g/ml} \) (Mucor spp.) and \( >16 \mu \text{g/ml} \) (Fusarium proliferatum) were observed for the two tested molds.

The frequency and rationale for the early discontinuation of posaconazole prophylaxis among courses that met NCCN criteria for prophylaxis are shown in Table 4. Posaconazole prophylaxis was discontinued early in 15.5% of the courses; suspension

| Characteristic                                                                 | Unadjusted HR (95% CI) | Adjusted HR (95% CI) |
|-------------------------------------------------------------------------------|------------------------|----------------------|
| Tablet formulation                                                            | 1.1 (0.4–3.1)          | 1.2 (0.4–3.4)        |
| Nasogastric tube administration                                                | 23.9 (4.6–83.4)        | 34.1 (6.3–128.9)     |
| Male sex                                                                      | 2.0 (0.7–7.8)          | 2.2 (0.7–8.6)        |
| Antiviral therapy                                                             | 0.4 (0.1–1.1)          | 0.4 (0.1–1.2)        |
| Underlying diagnosis (cancer vs GVHD and other high-dose steroid use)         | 1.5 (0.5–5.9)          |                      |
| Antibiotic therapy                                                            | 0.9 (0.2–8.5)          |                      |
| Proton pump inhibitors                                                        | 0.5 (0.2–1.4)          |                      |
| Mucositis                                                                     | 2.5 (0.6–7.5)          | 4.6 (1.0–17.5)       |
| Met NCCN criteria for prophylaxis                                             | 1.3 (0.3–12.0)         |                      |
| Posaconazole level taken during course                                         | 1.0 (0.4–2.8)          |                      |
| Age > 65 years                                                                | 2.6 (0.9–7.1)          | 3.7 (1.2–12.1)       |
| BMI > 30 (kg/m²)                                                             | 0.6 (0.2–1.9)          |                      |

*Data are for 860 courses. GVHD, graft-versus-host disease; NCCN, National Comprehensive Cancer Network; BMI, body mass index.*
| Patient No. | Age (yr) | Sex | Underlying diagnosis | HSCT (year) | Posaconazole formulation | EORTC classification | Probable criteria | Site of infection | Identified fungal organism | No. of days after start of prophylaxis | Posaconazole level (µg/ml) |
|------------|----------|-----|----------------------|-------------|--------------------------|----------------------|-------------------|-----------------|----------------------------|-------------------------------|--------------------------|
| 1          | >65      | F   | APL                  | No          | Suspension               | Probable             | Host factor, neutropenia; clinical criteria, tracheobronchial plaques on bronchoscopy; mycological criteria, *Aspergillus fumigatus* from bronchoalveolar lavage fluid | Lung/trachea | *Aspergillus fumigatus* | 15                           | NC                         |
| 2          | No       | F   | CML                  | No          | Suspension               | Probable             | Host factor, neutropenia; clinical criteria, CT of the chest with multiple pulmonary nodules and focal peribronchial consolidation; mycological criteria, positive galactomannan | Lung          | Positive galactomannan only | 18                           | 0.28                       |
| 3          | Yes      | M   | AML                  | No          | Suspension               | Proven               | Host factor, neutropenia; clinical criteria, CT with numerous bilateral small consolidative nodules; mycological criteria, positive galactomannan | Lung          | *Fusarium proliferatum* | 17                           | 1.82                       |
| 4          | Yes      | M   | AML                  | No          | Tablet                   | Probable             | Host factor, neutropenia; clinical criteria, CT with numerous bilateral small consolidative nodules; mycological criteria, positive galactomannan | Lung          | Positive galactomannan only | 25                           | 1.80                       |
| 5          | Yes      | M   | AML                  | No          | Tablet                   | Proven               | Lung factor, neutropenia; clinical criteria, CT with multiple pulmonary nodules and focal peribronchial consolidation; mycological criteria, positive galactomannan | Lung          | Positive cryptococcal antigen only | 13                           | NC                         |
| 6          | No       | M   | GVHD Allogeneic (2004)| Suspension | Proven                   |                                   |                                   | Blood           | *Candida glabrata* | 12                           | 1.07                       |
| 7          | No       | M   | AML                  | No          | Table     | Proven                   |                                   | Sinuses         | *Mucor sp.* | 66                           | 0.90                       |
| 8          | Yes      | M   | AML                  | No          | Table     | Proven                   |                                   | Sinuses         | *Zygomycetes sp.* | 13                           | NC                         |
| 9          | No       | M   | AML                  | No          | Suspen   | Proven                   |                                   | Lung            | *Aspergillus niger* | 5                            | NC                         |
| 10         | No       | M   | AML                  | No          | Suspen   | Proven                   |                                   | Lung            | Positive galactomannan only | 7                            | NC                         |
| 11         | No       | F   | Allogeneic HSCT (2012)| Suspension | Proven                   |                                   |                                   | Lung            | *Aspergillus sp.* | 44                           | 2.09                       |
| 12         | No       | M   | GVHD Allogeneic (2012)| Tablet     | Proven                   |                                   |                                   | Blood           | *Candida glabrata* | 78                           | 1.20                       |
| 13         | No       | M   | AML                  | No          | Tablet     | Proven                   |                                   | Sinuses         | No culture growth | 39                           | NC                         |
| 14         | Yes      | M   | AML                  | No          | Tablet     | Proven                   |                                   | Blood           | *Candida tropicalis* | 13                           | 1.60                       |

*Data are for 14 patients. F, female; M, male; HSCT, hematopoietic stem cell transplantation; EORTC, European Organization for Research and Treatment of Cancer; CT, computed tomography; APL, acute promyelocytic leukemia; CML, chronic myeloid leukemia; AML, acute myeloid leukemia; GVHD, graft-versus-host disease; NC, not collected.*
courses were less likely to be discontinued early than tablet courses, but the difference was not statistically significant (14.6% versus 16.5%; 95% CI for difference, −0.13 to 0.06). The most frequent reasons for early discontinuation were elevated liver function tests (27.8%), an inability to take the oral formulation (20.9%), and cost (18.3%). Additionally, 14 patients discontinued prophylaxis as part of changes in goals of care but were not included as early discontinuations. There were no statistically significant differences in the early discontinuation rationale between suspension courses and tablet courses ($P = 0.26$). Among the 115 patients who had early the discontinuation of posaconazole prophylaxis, 27 (23.5%) had at least one additional course of posaconazole prophylaxis after early discontinuation.

The observed mortality rate while receiving posaconazole for patients receiving the oral suspension formulation was 1.8 per 10,000 posaconazole days, and that for patients receiving the tablet formulation was 1.1 per 10,000 posaconazole days (RR = 1.1, 95% CI = 0.2 to 9.6).

**DISCUSSION**

In this large, retrospective cohort study of patients receiving posaconazole prophylaxis, the incidence of breakthrough IFIs was low and not significantly different between patients receiving the tablet and those receiving the oral suspension formulation. Posaconazole prophylaxis was discontinued while still indicated in 17% of courses; however, the frequency of discontinuation was also not significantly different between the two formulations. The primary reasons for early discontinuation were elevated liver function tests, an inability to take an oral formulation, and drug cost. These data support the suggestion that breakthrough IFIs are rare among patients receiving posaconazole prophylaxis and that safety and effectiveness endpoints are similar between the tablet and oral suspension formulations.

To our knowledge, only three previous studies have compared the incidence of breakthrough IFIs between the oral suspension and tablet formulations of posaconazole (9–11). One study was of 63 pediatric patients with hematologic malignancies in Germany in which no IFIs were identified (10). The second included 152 patients with AML or myelodysplastic syndrome (MDS), and the authors reported an overall IFI incidence of 7% but did not observe a significant difference between the two formulations (9). However, breakthrough IFIs were a secondary endpoint, and the study was not powered to assess differences regarding this outcome. Furthermore, 4/8 cases of IFIs were possible IFIs rather than probable or proven IFIs. Subtracting these patients from the outcome group results in an incidence of 3.5%, which is closer to the 1.6% observed in our study and consistent with data from randomized controlled trials of posaconazole prophylaxis (6, 12). The most recent study included only 61 patients, with only 1 patient experiencing an IFI (11).
Among the 14 cases of proven or probable IFIs in our study, 8 cases had documented posaconazole serum concentration measurements, and the concentrations in 7 of these patients were above the proposed therapeutic level of 0.7 μg/ml. This proposed target level is based on limited evidence which was derived from a secondary analysis of two phase 3 clinical trials which demonstrated an exposure-response relationship between posaconazole levels and clinical failure (13). However, that analysis utilized a composite endpoint of clinical failure that was not aligned with the primary endpoint in either of the phase 3 trials contributing data (14). Additional studies also support the exposure-response relationship for both prophylaxis and treatment with recommended target levels ranging from 0.5 to 1.25 μg/ml, although these studies were limited by small sample sizes and a lack of antifungal susceptibility data (15–18). Our study and others support the superiority of the tablet over the suspension in achieving target serum concentrations (8, 11, 19). Our finding that IFIs occurred despite achieving these targets has been observed in a recent cohort study and also supports a reexamination of the proposed target concentration, the association between serum and infection site concentrations, and the value of routine monitoring for achievement of the current target (20). However, we also recognize the relative rarity of IFIs among patients receiving posaconazole prophylaxis, the associated costs of routine monitoring, and the fact that other factors beyond pharmacokinetic and/or pharmacodynamic properties contribute to the incidence of breakthrough IFIs.

We observed that 17% of patients discontinued posaconazole despite a still present indication for prophylaxis based on NCCN criteria. The primary documented rationales for early discontinuation were elevated liver function tests, an inability to take an oral formulation, and drug cost. There were no significant differences in the frequency or distribution of the rationale for early discontinuation between formulations, which is consistent with the findings reported from previous studies (9, 21). Evaluation of the clinical outcomes of patients that discontinued posaconazole was beyond the scope of this study, but they should be explored to better understand the relative trade-offs between those outcomes and the rationale for discontinuation.

Given that this was an observational study, the posaconazole formulation was not randomly assigned and thus is subject to potential confounding by indication. However, the impact of this bias is likely minimal given the temporal preference for the different formulations; i.e., once the tablet formulation was available, nearly all prescribers ceased using the suspension. Furthermore, the only significant differences between oral suspension and tablet courses were that oral suspension courses were more likely to be administered using a nasogastric tube, the patients receiving oral suspension courses also received antibiotic therapy, and the patients receiving oral suspension courses experienced mucositis during their posaconazole course. Previous studies have also reported minimal differences in patient characteristics between patients who received the different formulations, and these differences were unlikely to influence our clinical outcomes (9, 22). After adjusting for formulation and course characteristics, nasogastric tube administration was associated with breakthrough IFIs; this may be because of the strong correlation with disease severity or suboptimal infection site drug concentrations. Regarding the difference in mucositis incidence between the two formulations, our study was not designed to explore this association. Chemotherapy is known to cause mucositis; however, there was no significant difference in the distribution of chemotherapeutic agents between patients receiving the two formulations. The only other study to quantify this association also observed a higher incidence of mucositis among patients who received the oral suspension formulation; however, that difference was not statistically significant (9).

The primary limitation of this study was that our retrospective study design required reliance on medical record documentation for determination of IFIs and the frequency and rationale for posaconazole discontinuation. As such, there is some potential for misclassification of these outcomes. In addition, our study was limited in its ability to address temporal changes in antifungal resistance or the incidence of IFIs. Temporal changes and a lack of randomization may also contribute to the observation that, while
the difference was small (<1/10,000 posaconazole days) and not statistically significant, the incidence of IFIs was higher among patients who received the tablet formulation. Lastly, despite this being the largest cohort study of patients receiving posaconazole prophylaxis, the results of this single-site study may not be generalizable to other centers and patient populations, where practice patterns and the prevalence of antifungal resistance may vary.

In conclusion, we observed no significant difference in breakthrough IFIs between patients receiving oral suspension and tablet formulations of posaconazole prophylaxis, despite the significantly higher frequency of target level attainment among patients receiving the tablet formulation. Further work is needed to better identify target posaconazole levels, particularly in the context of increasing antifungal resistance.

MATERIALS AND METHODS

Study design and patient population. This was a retrospective cohort study of patients with a hematologic malignancy who received posaconazole prophylaxis for IFIs as either an inpatient or an outpatient at Oregon Health & Science University Hospitals and Clinics (OHSU) between 1 January 2010 and 30 June 2016. This study was approved by the OHSU institutional review board. OHSU is located in the Portland, OR, metropolitan area and includes a 576-bed academic, tertiary referral center with the Knight Cancer Institute, which performs over 150 hematopoietic stem cell transplants a year, with outpatient care being provided in the Center for Hematologic Malignancies of the Knight Cancer Institute, an NCI-designated Comprehensive Cancer Center. Consistent with clinical guidelines, IFI prophylaxis with posaconazole was provided during the study period for patients with neutropenia secondary to treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), an allogetic stem cell transplant, or treatment with high-dose steroids (>20 mg/day prednisone or equivalent) or when clinically indicated at the discretion of the physician (4, 23). At OHSU, the oral suspension of posaconazole was utilized for prophylaxis beginning in 2008 and was changed to the delayed-release tablet formulation in February 2014. After 1 February 2014, only 36 courses of the oral suspension were prescribed, and no courses of the oral suspension were prescribed after October 2015.

To be included in this analysis, patients must have received a minimum of 7 continuous days of posaconazole prophylaxis during the study period to ensure that drug serum concentrations were at steady state. Patients may have received multiple courses of posaconazole prophylaxis during the study period, and separate courses were defined as occurring more than 7 days after the end of the previous course. Patients could contribute multiple courses to the analysis until they had a probable or proven IFI.

Data sources. The primary data source for this study was the Pharmacy Research Repository (PHARR), a longitudinal repository of patient health care data created in partnership with the Oregon Clinical and Translational Institute (OCTRI) Research Data Warehouse (RDW) at OHSU. PHARR includes encounter, diagnosis, procedure, laboratory, and pharmacy data. For all study subjects, administrative, demographic, diagnosis, laboratory, and pharmacy data were extracted from that index encounter as well as all past and future encounters (inpatient and outpatient) within any OHSU setting. These data have been validated and used in previous epidemiologic studies of medication utilization and treatment outcomes (24, 25). In addition to these electronic data, we manually reviewed the medical records of all study patients to screen for candidate IFIs and confirm posaconazole start and stop dates to determine unique courses. We also confirmed the indication for posaconazole prophylaxis and the incidence and rationale for early discontinuation through medical record review. All manually extracted data were entered into a secure database using the Research Data Electronic Data Capture (REDCap) application and merged with electronically collected data from PHARR (26).

Variable definitions. Our primary exposure of interest was the formulation of posaconazole used for prophylaxis (i.e., either the delayed-release tablet or the oral suspension). The drug formulation was determined using pharmacy orders and the medication administration record. Prophylaxis (versus active treatment) was determined using a combination of duration of therapy, dosage, and frequency and confirmed using microbiology, timing, diagnosis data, and documentation in the medical record to rule out posaconazole treatment of proven or probable IFIs.

Our primary outcome of interest was breakthrough IFIs, which were defined as IFIs occurring while the patient was receiving posaconazole prophylaxis. Patients with candidate IFIs were identified during medical record review by changes in antifungal therapy or addition of an additional antifungal agent(s), positive fungal biomarkers (e.g., Aspergillus galactomannan, 16S rRNA sequencing results), or clinician documentation of an IFI or a suspicion of an IFI. All patients with a candidate IFI were reviewed by a clinical expert panel consisting of an infectious disease pharmacist (J.S.L.), oncology pharmacist (J.S.B.), and infectious disease physician (G.N.F.) to identify proven or probable IFIs based on European Organization for Research and Treatment of Cancer (EORTC) definitions (27). Two reviewers were randomly selected to independently review each patient. If there was disagreement, a third reviewer broke ties.

Our secondary outcome of interest was the discontinuation of posaconazole while it was still indicated; i.e., patients still met the National Comprehensive Cancer Network (NCCN) criteria for prophylaxis. Patients who did not initially meet the NCCN criteria were not evaluated for early discontinuation. Early discontinuation was defined using pharmacy orders and the medication administration record to identify initiation of a new systemic antifungal therapy and posaconazole discontinuations that occurred during the expected duration of prophylaxis. We then manually reviewed each medical record.
to determine the reason for early discontinuation. If the rationale for discontinuation was not explicitly stated in the medical record, two external reviewers (J.S.B., J.S.L., or G.N.F.) reviewed each patient, and ties were broken as described above for determination of IFIs.

We also collected data on other patient characteristics of interest, including demographics (e.g., age, sex), indications for IFI prophylaxis, the presence of comorbid illnesses and neutropenia, trough levels of posaconazole, and other medications that the patients were receiving (e.g., chemotherapy regimen, antibiotics, antiviral therapy, proton pump inhibitors) (23). Indications for prophylaxis and comorbid illnesses were defined using encounter diagnosis codes (International Classification of Diseases, versions 9 [ICD-9] and 10 [ICD-10]) from encounter and problem list diagnoses.

Statistical analysis. We used descriptive statistics, including means and standard deviations (SDs), medians and interquartile ranges (IQRs), and proportions, to summarize the characteristics of the patients and the treatment courses of the oral suspension and tablet formulations of posaconazole. The characteristics of the patients and treatment courses were compared between formulations using two-sample t tests, chi-squared tests, Fisher's exact test, and the Wilcoxon rank sum test as appropriate. We assessed within-subject correlations since patients could have multiple treatment courses. We calculated the observed rate of IFIs for each formulation along with the rate ratio (RR) and the exact 95% confidence intervals (CIs) using the conditional maximum likelihood estimate.

We performed Cox proportional hazards modeling to account for various lengths of follow-up and to adjust for potential confounders when estimating the effect of the posaconazole formulation on breakthrough IFIs. Since the occurrence of IFIs was rare, we used penalized Cox proportional hazards regression using Firth's correction to account for the high percentage of censoring (i.e., monotone likelihood). We considered unadjusted and adjusted hazard ratios (HRs) and the corresponding 95% penalized profile-likelihood CIs. Variables were selected for inclusion in the model using Akaike information criterion (AIC) optimization within best subset selections with the posaconazole formulation forced into the model. To identify if associations remained consistent within the subset of the patients' first course of posaconazole, a sensitivity analysis was performed.

We compared the frequency of the early discontinuation of posaconazole and the documented reason for discontinuation between the two formulations using the chi-squared test. We also calculated the rate of death within 30 days after the conclusion of posaconazole prophylaxis and death while receiving posaconazole for each formulation, in addition to the RR and exact 95% confidence intervals, using the conditional maximum likelihood estimate. P values of less than 0.05 were considered statistically significant. All statistical analyses were performed using SAS statistical software, version 9.2 (SAS Institute, Cary, NC).

ACKNOWLEDGMENTS

This work was supported by funding from Merck & Co., Inc., Kenilworth, NJ, USA, and by the Oregon Clinical and Translational Research Institute, funded by the National Center for Advancing Translational Sciences (grant number UL1TR000128). B.R.W. was supported by an American Foundation for Pharmaceutical Education Gateway to Research Scholarship.

J.P.F. is a paid consultant by Shinogi Inc., Florham Park, NJ, USA, and Merck & Co., Inc., Kenilworth, NJ, USA, and has received research grants and speaking honoraria from Merck & Co., Inc., Kenilworth, NJ, USA; G.B.T., B.N.N., G.N.F., A.F.B., C.A.H., and B.R.W. have no conflicts; J.S.B. has received advisory board honoraria in oncology supportive care from Merck & Co., Inc., Kenilworth, NJ, USA; J.S.L. is a paid consultant for Merck & Co., Inc., Kenilworth, NJ, USA; and J.C.M. has received research grants and speaking honoraria from Merck & Co., Inc., Kenilworth, NJ, USA.

Acquisition of funding was by J.P.F. and J.C.M., study concept and design were by J.P.F., J.C.M., B.N.N., and G.B.T., acquisition of data was by all authors, analysis of the data was by J.P.F., J.C.M., B.N.N., and G.B.T., interpretation of results was by all authors, preparation of the initial draft of the manuscript was by J.P.F., J.C.M., B.N.N., and G.B.T., and critical review of the manuscript was by all authors.

REFERENCES

1. Baddley JW. 2011. Clinical risk factors for invasive aspergillosis. Med Mycol 49(Suppl 1):S57–S12. https://doi.org/10.3109/13693786.2010.505204.
2. Patterson TF. 2009. Risk stratification for invasive aspergillosis: early assessment of host susceptibility. Med Mycol 47(Suppl 1):S255–S260. https://doi.org/10.1080/13693780802718339.
3. Petrikkos G, Skia A, Lortholary O, Rollides E, Walsh TJ, Kontoyiannis DP. 2012. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 54(Suppl 1):S23–S34. https://doi.org/10.1093/cid/cir866.
4. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR. Infectious Diseases Society of America. 2011. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56–e93. https://doi.org/10.1093/cid/cir073.
5. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF, Infectious Diseases Society of America. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327–360. https://doi.org/10.1086/525258.
10. Doring M, Cabanillas Stanchi KM, Queudeville M, Feucht J, Blaeschke F, Schlegel P, Feuchtinger T, Lang P, Muller I, Handgretinger R, Heinz WJ. 2017. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation. J Cancer Res Clin Oncol 143:1281–1292. https://doi.org/10.1007/s00432-017-2369-7

11. Lenczkowski, Zinke-Cerwenka W, Greinix H, Wolfler A, Prattes J, Zollner-Lientz, Lin TC, Meinitzer A, Hoenigl M, Krause R. 2018. Antifungal prophylaxis with posaconazole delayed-release tablet and oral suspension in a real-life setting: plasma levels, efficacy, and tolerability. Antimicrob Agents Chemother 62:e02655-17. https://doi.org/10.1128/AAC.02655-17.

12. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Taran-tolo SR, Greinix H, Morales de Azavedo W, Reddy V, Boparai N, Pedicone L, Patino-Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Perfect JR, Ribaud P, Segal BH, Stevens DA, van Burik JA, White CS, Corcoran G, Gogate J, Krishna G, Pedicone L, Hardalo C, Perfect JR. 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44:2–12. https://doi.org/10.1086/508774.

13. Berking S, Doedens D, Horns H, Feigl M, Ostermann H, Rieger CT. 2017. Antifungal prophylaxis in newly diagnosed AML patients—adherence to guidelines and feasibility in a real life setting. Mycoses 60:500–506. https://doi.org/10.1111/myc.12635.

14. Connelly OA, Ullmann AJ. 2011. Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections. Clin Pharmacol Ther 89:351–352. https://doi.org/10.1038/cpt.2010.64.

15. Eiden C, Meniane JC, Peyrièrre H, Eymard-Duvermay S, Le Falher G, Ceballos P, Fegueux N, Cocciglio M, Reynes J, Hillaire-Buys D. 2012. Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake. Eur J Clin Pharmacol Ther 61:e00188-17. https://doi.org/10.1128/AAC.00188-17.

16. Lebeaux D, Lanternaire F, Elie C, Suarez F, Buzyn A, Viard JP, Bougnoux ME, Lecuit M, Jullien V, Lortholary O. 2009. Therapeutic drug monitoring of posaconazole: a monocentric study with S4 adults. Antimicrob Agents Chemother 53:5224–5229. https://doi.org/10.1128/AAC.00939-09.

17. Shields RK, Clancy CJ, Vadnerkar A, Kawk EJ, Silveira FP, Massih RC, Pilewski JM, Crespo M, Toyoda Y, Bhamra JK, Bermudez C, Nguyen MH. 2011. Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy. Antimicrob Agents Chemother 55:1308–1311. https://doi.org/10.1128/AAC.01325-10.

18. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hackem R, Hadley S, Herbrecht R, Langston A, Louie A, Ribaud P, Segal BH, Stevens DA, van Burik JA, White CS, Corcoran G, Gogate J, Krishna G, Pedicone L, Hardalo C, Perfect JR. 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44:2–12. https://doi.org/10.1086/508774.